
    
      This will be a single-center, single-arm, open label PK clinical study of loteprednol
      etabonate (LE) ophthalmic gel, 0.38% conducted at one clinical center in the United States
      (US), with the goal of enrolling approximately 15 healthy normal subjects in the treatment
      period
    
  